Our results also confirm the reduction in the brain-enriched sphingomyelin synthases SGMS1 and SGMS2 also in human AD neocortex and hippocampus (Fig. 6), suggesting a deficiency in the capability to synthesize sufficient amounts of sphingomyelin in anatomical regions of the brain targeted by the AD process. The gene discussed is SGMS2; the disease is Alzheimer disease.